González-Romero DM, Noffal-Nuńo VM

Language: Spanish
References: 17
Page: 110-113
PDF size: 124.47 Kb.

ABSTRACT

Anti-Müllerian hormone is a glycoprotein produced by the granulosa cells of developing ovarian follicles which is used as a serum marker to assess the ovarian reserve, since its concentration has been correlated with the number of available follicles, as well as has been shown to be a good endocrine marker, providing more reliable information than the one provided by follicle stimulating hormone, estradiol and inhibin B measurements, that are used as part of the initial evaluation of women who will be exposed to in vitro fertilization procedures. Another feature that makes it to be a good marker, is that shows few variations in its concentration during the different stages of the menstrual cycle, which allows its assessment at any time, thus making easier the results interpretation for a better fertility evaluation. Is critical that the laboratory which performs this test, get clinical information related to the diagnosis and treatment received by the patient, in order to provide an appropriate reference range together with the result report, to offer the precise information that the clinician requires and then to promote a good laboratory-physician interaction for the benefit of the evaluated patient.

REFERENCES

1. Grynnerup A, Lindhard A, Sorensen S. The role of anti-Müllerian hormone in female fertility and infertility – an overview. Acta Obstet Gynecol Scand 2012; 91: 1252-60.

2. Bhide P, Shah A, Gudi A, Homburg R. The role of anti-müllerian hormone as a predictor of ovarian function. The Obstetrician & Gynaecologist 2012; 14: 161-6.

3. La Marca A, Volpe A. Anti-Müllerian hormone (AMH) in female reproduction: is measurement of circulating AMH a useful tool? Clin Endocrinol 2006; 64: 603-10.

4. Yeup-Lee J, Chul-Jee B, Ryeol-Lee J, Hyon-Kim C, Park T, Ra- Yeon B, Yeon-Seo S, et al. Age-related distributions of anti- Mullerian hormone level and anti-Mullerian hormone models. Acta Obstet Gynecol Scand 2012; 970-5.

5. Seifer DB, Baker VL, Leader B. Age-specific serum anti-Müllerian hormone values for 17,120 women presenting to fertility centers within the United States. Fertil Steril 2011; 95: 747-50.

6. Broer SL, Eijkemans MJ, Scheffer GJ, van Rooij IA, de Vet A, Themmen AP, Laven JS, et al. Anti-mullerian hormone predicts menopause: a long-term follow-up study in normoovulatory women. J Clin Endocrinol Metab 2011; 96: 2532-9.

7. La Marca A, Sighinolfi G, Radi D, Argento C, Baraldi E, Artenisio AC, Stabile G, et al. Anti-Mü¨llerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum Reprod 2010; 16: 113-30.

8. La Marca A, Broekmans FJ, Volpe A, Fauser BC, Macklon NS. Anti-Müllerian hormone (AMH): what do we still need to know? Hum Reprod 2009; 24: 2264-75.

9. Godoy HS, Ulloa A, Falcón JC, Marsai EE, Rivas R, Cedillo L. Hormona antimülleriana como marcador de respuesta ovárica en fertilización in vitro. Ginecol Obstet Mex 2012; 80(1): 1-7.

10. Ebner T, Sommergruber M, Moser M, Shebl O, Schreier-Lechner E, Tews G. Basal level on anti-müllerian hormone is associated with oocyte quality in stimulated cycles. Hum Reprod 2006; 21: 2002-6.

11. Unger S, Beraja H. Hormona antimülleriana. Reserva ovárica y reserva testicular. Reproducción 2010; 25: 137-53.

12. Wang JG, Douglas NC, Nakhuda GS, Choi JM, Park SJ, Thornton MH, Guarnaccia MM, et al. The association between anti- Mullerian hormone and IVF pregnancy outcomes is influenced by age. Reprod Biomed Online 2010; 21: 757-61.

13. Klinkert ER, Broekmans FJ, Looman CW, Habbema JD, te Velde ER. Expected poor responders on the basis of an antral follicle count do not benefit from a higher starting dose of gonadotrophins in IVF treatment: a randomized controlled trial. Hum Reprod 2005; 20: 611-5.

14. Nelson SM, Yates RW, Lyall H, Jamieson M, Traynor I, Gaudoin M, Mitchell P, et al. Anti-Mullerian hormone-based approach to controlled ovarian stimulation for assisted conception. Hum Reprod 2009; 24: 867-75.

15. Practice Committee of American Society for Reproductive Medicine. Ovarian hyperstimulation syndrome. Fertil Steril 2008; 90: S188-S193.

16. Tummon I, Gavrilova-Jordan L, Allemand MC, Session D. Polycystic ovaries and ovarian hyper stimulation syndrome: a systematic review. Acta Obstet Gynecol Scand 2005; 84: 611-6.

17. Lee TH, Liu CH, Huang CC, Wu YL, Shih YT, Ho HN, Yang YS. Serum anti- Müllerian hormone and oestradiol levels as predictors of ovarian hyperstimulation syndrome in assisted reproduction technology cycles. Hum Reprod 2008; 23: 160-7.